Even in comparison to its direct obesity/ diabetes therapy pharmaceutical peer, LLY at FWD P/E valuations of 58.71x Using the projected adj EPS progress in a CAGR of +65.4% by means of FY2026, it really is simple that https://junaidgnoi727617.life3dblog.com/28565828/about-why-am-i-not-losing-weight-on-wegovy